Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Lee, Duk Joo ^a   Lee, Jeeyun ^a   Lee, Ha Yeon ^a   Lim, Taekyu ^a   Lee, Su Jin ^a   Yi, Seong Yoon ^b   Park, Se Hoon ^a   Park, Joon Oh ^a   Lim, Ho Yeong ^a   Kang, Won Ki ^a   Park, Young Suk ^a  

^a Sungkyunkwan University   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Metatstatic colorectal cancer; S 1; Salvage therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LIVER METASTASIS; LUNG METASTASIS; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; RASH; SALVAGE THERAPY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84655176666     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9755-1     Document Type: Article

References (13)

1. D Machover 1997 A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma Cancer 80 1179 1187
2. W Scheithauer H Rosen GV Kornek C Sebesta D Depisch 1993 Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer BMJ 306 752 755 (Pubitemid 23080053)
3. P Thirion 2004 Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis J Clin Oncol 22 3766 3775
4. JA Meyerhardt RJ Mayer 2005 Systemic therapy for colorectal cancer N Engl J Med 352 476 487
5. T Shirasaka 2009 Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas Jpn J Clin Oncol 39 2 15
6. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 cooperative gastric cancer study group Oncology 58 191 197 (Pubitemid 30189900)
7. A Ohtsu 2000 Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 cooperative colorectal carcinoma study group Br J Cancer 83 141 145 (Pubitemid 30411708)
8. K Shirao 2004 Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma Cancer 100 2355 2361 (Pubitemid 38657882)
9. T Okusaka 2008 A late phase II study of S-1 for metastatic pancreatic cancer Cancer Chemother Pharmacol 61 615 621
10. P Therasse 2000 New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada J Natl Cancer Inst 92 205 216
11. JS de Bono CJ Twelves 2001 The oral fluorinated pyrimidines Invest New Drugs 19 41 59 (Pubitemid 32209784)
12. T Shirasaka 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557 (Pubitemid 26276346)
13. M Gubanski G Naucler A Almerud A Lidestahl PA Lind 2005 Capecitabine as third line therapy in patients with advanced colorectal cancer Acta Oncol 44 236 239 (Pubitemid 40904126)